Stada Arzneimittel Aktiengesellschaft Stock Gross Profit
STADA Arzneimittel Aktiengesellschaft fundamentals help investors to digest information that contributes to STADA Arzneimittel's financial success or failures. It also enables traders to predict the movement of STADA OTC Stock. The fundamental analysis module provides a way to measure STADA Arzneimittel's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to STADA Arzneimittel otc stock.
STADA |
STADA Arzneimittel Aktiengesellschaft OTC Stock Gross Profit Analysis
STADA Arzneimittel's Gross Profit is the most basic measure of business operational efficiency. It is simply the difference between sales revenue and the cost associated with making a product or providing a service. It is calculated before deducting administrative expenses, taxes, and interest payments.
Current STADA Arzneimittel Gross Profit | 1.37 B |
Most of STADA Arzneimittel's fundamental indicators, such as Gross Profit, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, STADA Arzneimittel Aktiengesellschaft is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Gross Profit varies significantly from one sector to another and tells an investor how much money a business would have made if it didn't have to pay any overhead expenses such as salary, taxes, or rent.
CompetitionAccording to the company disclosure, STADA Arzneimittel Aktiengesellschaft reported 1.37 B of gross profit. This is 38.93% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The gross profit for all United States stocks is 95.0% higher than that of the company.
STADA Gross Profit Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses STADA Arzneimittel's direct or indirect competition against its Gross Profit to detect undervalued stocks with similar characteristics or determine the otc stocks which would be a good addition to a portfolio. Peer analysis of STADA Arzneimittel could also be used in its relative valuation, which is a method of valuing STADA Arzneimittel by comparing valuation metrics of similar companies.STADA Arzneimittel is currently under evaluation in gross profit category among related companies.
STADA Fundamentals
| Return On Equity | 22.55 | |||
| Return On Asset | 6.39 | |||
| Profit Margin | 9.00 % | |||
| Current Valuation | 6.87 B | |||
| Shares Outstanding | 62.26 M | |||
| Shares Owned By Institutions | 0.30 % | |||
| Price To Earning | 22.46 X | |||
| Price To Book | 4.54 X | |||
| Price To Sales | 2.11 X | |||
| Revenue | 2.69 B | |||
| Gross Profit | 1.37 B | |||
| EBITDA | 559.98 M | |||
| Net Income | 252.03 M | |||
| Cash And Equivalents | 502.02 M | |||
| Cash Per Share | 8.06 X | |||
| Total Debt | 1.73 B | |||
| Debt To Equity | 2.58 % | |||
| Current Ratio | 1.49 X | |||
| Book Value Per Share | 20.02 X | |||
| Cash Flow From Operations | 347.14 M | |||
| Earnings Per Share | 4.05 X | |||
| Number Of Employees | 12.34 K | |||
| Beta | 0.35 | |||
| Market Capitalization | 6.87 B | |||
| Total Asset | 3.46 B | |||
| Retained Earnings | 686 M | |||
| Working Capital | 604 M | |||
| Current Asset | 1.49 B | |||
| Current Liabilities | 887 M | |||
| Z Score | 1.8 | |||
| Last Dividend Paid | 0.11 |
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios. Also, note that the market value of any otc stock could be tightly coupled with the direction of predictive economic indicators such as signals in nation. Note that the STADA Arzneimittel information on this page should be used as a complementary analysis to other STADA Arzneimittel's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.
Other Consideration for investing in STADA OTC Stock
If you are still planning to invest in STADA Arzneimittel check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the STADA Arzneimittel's history and understand the potential risks before investing.
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device |